What one share of VivoSim Labs holds
VivoSim Labs, Inc. ("VivoSim," “we,” “us,” “our,” the “Company” and “our Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine.
VivoSim Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.03 |
|---|---|
| Profit | −$3.77 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.10 |
| Cash and investments | $0.52 |
| Book value | −$0.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | $9.90 | −$21.98 | $0.79 | −$14.25 | — | −$37.77 |
| 2011 | $10.14 | −$45.88 | $0.48 | −$20.52 | — | −$19.62 |
| 2012 | $6.66 | −$242.24 | $1.99 | −$55.90 | — | −$21.74 |
| 2014 | $1.24 | −$84.82 | $0.91 | −$51.97 | — | $148.35 |
| 2015 | $1.72 | −$90.64 | $4.57 | −$63.63 | — | $143.33 |
| 2016 | $3.95 | −$102.80 | $5.63 | −$83.90 | — | $161.52 |
| 2017 | $10.38 | −$94.38 | $3.32 | −$74.97 | — | $143.15 |
| 2018 | $10.30 | −$77.89 | $0.51 | −$65.08 | — | $96.37 |
| 2019 | $6.43 | −$55.40 | $0.16 | −$42.55 | — | $70.25 |
| 2020 | $4.07 | −$33.60 | $0.00 | −$27.57 | — | $48.95 |
| 2021 | $0.00 | −$29.25 | $0.70 | −$23.87 | — | $54.25 |
| 2022 | $2.07 | −$15.78 | $0.56 | −$12.22 | — | $41.62 |
| 2023 | $0.51 | −$23.77 | $0.55 | −$17.63 | — | $21.10 |
| 2024 | $0.14 | −$19.25 | $0.06 | −$19.28 | — | $4.29 |
| 2025 | $0.10 | −$1.70 | $0.01 | −$6.47 | — | $5.53 |
| 2026 | $0.05 | −$5.35 | $0.00 | −$4.18 | — | −$0.38 |
Common questions about VivoSim Labs
How much does one share of VivoSim Labs earn?
Over the last 12 months, VivoSim Labs lost $3.77 for each share on $0.03 of sales.
Does VivoSim Labs pay a dividend?
VivoSim Labs didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is VivoSim Labs’s book value per share?
VivoSim Labs’s book value is negative (−$0.73 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of VivoSim Labs have?
Each share of VivoSim Labs has $0.52 of cash and investments, as of June 30, 2026.
What is VivoSim Labs’s free cash flow per share?
−$3.10 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has VivoSim Labs bought back shares?
VivoSim Labs’s share count rose about 4149% from 2010 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.